Nyrada Inc is a new US biotechnology company. Our business is drug discovery and drug development in areas of significant community need in the cardiovascular field. Our clinical targets are diseases and conditions affecting large numbers of individuals, where current treatment options are viewed as being poor, and in some cases, non-existent.
The guiding principles driving our commercial strategies are:
Sound scientific rationale
Significant unmet clinical need
Large market opportunity
Lack of competition
Strong IP protection
Favourable regulatory pathway to approval
Nyrada has 3 pipeline drugs under development. Each is first-in-class and pre-clinical.
NYX-330. A cholesterol-lowering drug. A small molecule inhibitor of PCSK9 for the treatment of individuals with blood LDL (low density lipoprotein) cholesterol levels considered 'at risk' of cardiovascular disease (hypertension, heart attack, stroke). NYX-330 is being developed as an oral drug to be used in combination with the standard statin cholesterol-lowering drugs, or for use in individuals unable to use statins for safety reasons.
NYX-104. A neuro-protectant drug. An inhibitor of phospholipase c beta activity, intended to protect the brain from glutamate-initiated excitotoxicity following ischaemic stroke. Excitotoxicity is a well-recognized, key mechanism for damage to the brain, which occurs in the hours and days following a stroke or traumatic brain injury such as concussion or accident. Currently there are no drugs approved that block excitotoxicity and offer the ability to limit the extent of damage to the brain following injury.
NYX-205. An anti-inflammatory drug. NYX-205 inhibits the enzyme, thromboxane synthase, blocking the production of thromboxane, a key component of inflammation associated with cardiovascular damage of a range of tissues such as the eye and kidneys in diabetic patients.